Meeting
2022 ASCO Annual Meeting
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.
Authors
Patricia LoRusso
Yale University, New Haven, CT
Patricia LoRusso , Drew W. Rasco , Geoffrey Shapiro , Alain C. Mita , Nilofer Saba Azad , Paul Swiecicki , Anthony B. El-Khoueiry , David R. Gandara , Shivaani Kummar , Hovig Tanajian , Jaruwan Taylor , Frank G Bottone Jr., Marchi Toguchi , Chris Hindley , Danna Chan , Aram Oganesian , Harold N. Keer , Kim-Hien T Dao , Ryan J. Sullivan , Alexander I. Spira
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03520075
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9085)
DOI
10.1200/JCO.2022.40.16_suppl.9085
Abstract #
9085
Poster Bd #
72
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2018 ASCO Annual Meeting
Phase 1 trial of trametinib alone and in combination with dabrafenib in children and adolescents with relapsed solid tumors or neurofibromatosis type 1 (NF1) progressive plexiform neurofibromas (PN).
First Author: Birgit Geoerger
Poster
2016 ASCO Annual Meeting
First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors.
First Author: Yong Sang Hong
Poster
2015 ASCO Annual Meeting
A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
First Author: Rebecca Sophie Kristeleit